Wed, Aug 20, 2014, 9:55 AM EDT - U.S. Markets close in 6 hrs 5 mins

Recent

% | $
Quotes you view appear here for quick access.

Astex Pharmaceuticals, Inc. Message Board

  • weightbayou weightbayou Jun 29, 2013 1:44 PM Flag

    Novartis is the collaborator. A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic

    A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia
    This study is currently recruiting participants.
    Verified June 2013 by NCIC Clinical Trials Group
    Sponsor:
    NCIC Clinical Trials Group
    Collaborators:
    Novartis Pharmaceuticals
    previously: Astex Pharmaceuticals
    Information provided by (Responsible Party):
    NCIC Clinical Trials GroupClinicalTrials.gov Identifier:
    NCT01627054
    First received: June 21, 2012
    Last updated: June 19, 2013
    Last verified: June 2013
    History of Changes

 
ASTX
8.4950.000(0.00%)Oct 10 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.